Q2 EPS Forecast for Acrivon Therapeutics Raised by Analyst

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Equities researchers at HC Wainwright upped their Q2 2026 earnings per share estimates for shares of Acrivon Therapeutics in a research report issued to clients and investors on Thursday, May 14th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.50) for the quarter, up from their previous estimate of ($0.57). The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($1.96) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($2.09) EPS, FY2027 earnings at ($1.47) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($0.67) EPS and FY2030 earnings at $0.13 EPS.

Several other research firms have also recently commented on ACRV. Weiss Ratings cut Acrivon Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Jefferies Financial Group reissued a “buy” rating on shares of Acrivon Therapeutics in a research note on Monday, March 2nd. Finally, Wall Street Zen cut Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, March 1st. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

Acrivon Therapeutics Stock Performance

NASDAQ ACRV opened at $1.65 on Tuesday. The stock has a fifty day moving average of $1.70 and a 200-day moving average of $1.93. The stock has a market capitalization of $70.62 million, a P/E ratio of -0.83 and a beta of 2.01. Acrivon Therapeutics has a 52 week low of $1.05 and a 52 week high of $3.56.

Acrivon Therapeutics (NASDAQ:ACRV) last released its earnings results on Wednesday, May 13th. The company reported ($0.49) EPS for the quarter, meeting the consensus estimate of ($0.49).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC boosted its position in shares of Acrivon Therapeutics by 18.3% in the 4th quarter. Jane Street Group LLC now owns 342,071 shares of the company’s stock worth $824,000 after purchasing an additional 52,823 shares during the last quarter. Two Sigma Investments LP boosted its position in shares of Acrivon Therapeutics by 76.2% in the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock worth $578,000 after purchasing an additional 138,033 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Acrivon Therapeutics by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 198,223 shares of the company’s stock worth $478,000 after acquiring an additional 6,190 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Acrivon Therapeutics by 504.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 119,422 shares of the company’s stock worth $288,000 after acquiring an additional 99,680 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Acrivon Therapeutics during the second quarter worth about $126,000. 71.62% of the stock is currently owned by institutional investors.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.